Baptiste GABORIEAU

Dr. Baptiste GABORIEAU

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2024 in Nature Microbiology
Verified
Journal Article
Closed access
PDF file
BGBaptiste GABORIEAU
Baptiste GABORIEAU
HVHugo Vaysset
Hugo Vaysset
FTFlorian Tesson
Florian Tesson
ICInès Charachon
Inès Charachon
NDNicolas Dib
Nicolas Dib
ABAude Bernheim
Aude Bernheim

17 May 2022 in Cell Reports
Verified
Journal Article
Open access
RDRaphaëlle Delattre
Raphaëlle Delattre
JSJérémy Seurat
Jérémy Seurat
FHFeyrouz Haddad
Feyrouz Haddad
TNThu-Thuy Nguyen
Thu-Thuy Nguyen
BGBaptiste GABORIEAU
Baptiste GABORIEAU
LDLaurent Debarbieux
Laurent Debarbieux
The clinical (re)development of bacteriophage (phage) therapy to treat antibiotic-resistant infections faces the challenge of understanding the dynamics of phage-bacteria interactions in the in vivo context. Here, we develop a general strategy coupling in vitro and in vivo experiments with a mathematical model to characterize the interplay between phage and bacteria during pneumonia induced by a pathogenic strain of Escherichia coli. The model allows the estimation of several key parameters for phage therapeutic efficacy. In particular, it quantifies the impact of dose and route of phage administration as well as the synergism of phage and the innate immune response on bacterial clearance. Simulations predict a limited impact of the intrinsic phage characteristics in agreement with the current semi-empirical choices of phages for compassionate treatments. Model-based approaches will foster the deployment of future phage-therapy clinical trials.

2 January 2025 in The ISME Journal
Verified
Journal Article
Open access
MBMagdalena Bürkle
Magdalena Bürkle
IKImke Korf
Imke Korf
ALAnne Lippegaus
Anne Lippegaus
SKSebastian Krautwurst
Sebastian Krautwurst
CRChristine Rohde
Christine Rohde
GKGopinath Krishnamoorthy
Gopinath Krishnamoorthy
Virulent bacteriophages (or phages) are viruses that specifically infect and lyse a bacterial host. When multiple phages co-infect a bacterial host, the extent of lysis and dynamics of bacteria–phage and phage–phage interactions are expected to vary. The objective of this study is to identify the factors influencing the interaction of two virulent phages with different Pseudomonas aeruginosa growth states (planktonic, an infected epithelial cell line, and biofilm) by measuring the bacterial time-kill and individual phage replication kinetics. A single administration of phages effectively reduced P. aeruginosa viability in planktonic conditions and infected human lung cell cultures, but phage-resistant variants subsequently emerged. In static biofilms, the phage combination displayed initial inhibition of biofilm dispersal, but sustained control was achieved only by combining phages and the meropenem antibiotic. In contrast, adherent biofilms showed tolerance to phage and/or meropenem, suggesting a spatio-temporal variation in the phage–bacterial interaction. The kinetics of adsorption of each phage to P. aeruginosa during single or co-administration were comparable. However, the phage with the shorter lysis time depleted bacterial resources early and selected a specific nucleotide polymorphism that conferred a competitive disadvantage and cross-resistance to the second phage. The extent and strength of this phage–phage competition and genetic loci conferring phage resistance are, however, P. aeruginosa genotype-dependent. Nevertheless, adding phages sequentially resulted in their unimpeded replication with no significant increase in bacterial host lysis. These results highlight the interrelatedness of phage–phage competition, phage resistance, and specific bacterial growth state (planktonic/biofilm) in shaping the interplay among P. aeruginosa and virulent phages.

22 October 2024 in Journal of Virology
Verified
Journal Article
Open access
BGBaptiste GABORIEAU
Baptiste GABORIEAU
RDRaphaëlle Delattre
Raphaëlle Delattre
SASandrine Adiba
Sandrine Adiba
OCOlivier Clermont
Olivier Clermont
EDErick Denamur
Erick Denamur
LDLaurent Debarbieux
Laurent Debarbieux
Bacteria exposed to bactericidal treatment, such as antibiotics or bacteriophages (phages), often develop resistance. While phage therapy is proposed as a solution to the antibiotic resistance crisis, the bacterial resistance emerging during phage therapy remains poorly characterized. In this study, we examined a large population of phage-resistant extra-intestinal pathogenic Escherichia coli 536 clones that emerged from both in vitro (non-limited liquid medium) and in vivo (murine pneumonia) conditions. Genome sequencing uncovered a convergent mutational pattern in phage resistance mechanisms under both conditions, particularly targeting two cell-wall components, the K15 capsule and the lipopolysaccharide (LPS). This suggests that their identification in vivo could be predicted from in vitro assays. Phage-resistant clones exhibited a wide range of fitness according to in vitro tests, growth rate, and resistance to amoeba grazing, which could not distinguish between the K15 capsule and LPS mutants. In contrast, K15 capsule mutants retained virulence comparable to the wild-type strain, whereas LPS mutants showed significant attenuation in the murine pneumonia model. Additionally, we observed that resistance to the therapeutic phage through a nonspecific mechanism, such as capsule overproduction, did not systematically lead to co-resistance to other phages that were initially capable or incapable of infecting the wild-type strain. Our findings highlight the importance of incorporating a diverse range of phages in the design of therapeutic cocktails to target potential future phage-resistant clones effectively. IMPORTANCE: This study isolated more than 50 phage-resistant mutants from both in vitro and in vivo conditions, exposing an extra-intestinal pathogenic Escherichia coli strain to a single virulent phage. The characterization of these clones revealed several key findings: (1) mutations occurring during phage treatment affect the same pathways as those identified in vitro ; (2) the resistance mechanisms are associated with the modification of two cell-wall components, with one involving receptor deletion (phage-specific mechanism) and the other, less frequent, involving receptor masking (phage-nonspecific mechanism); (3) an in vivo virulence assay demonstrated that the absence of the receptor abolishes virulence while masking the receptor preserves it; and (4) clones with a resistance mechanism nonspecific to a particular phage can remain susceptible to other phages. This supports the idea of incorporating diverse phages into therapeutic cocktails designed to collectively target both wild-type and phage-resistant strains, including those with resistance mechanisms nonspecific to a phage.

1 December 2020 in Journal of Critical Care
Verified
Journal Article
Closed access
CBC. Le Breton
C. Le Breton
SBSebastien Besset
Sebastien Besset
SFS. Freita-Ramos
S. Freita-Ramos
MAM. Amouretti
M. Amouretti
PBP.A. Billiet
P.A. Billiet
DRDamien Roux
Damien Roux

29 January 2023 in Viruses
Verified
Journal Article
Open access
PDF file
CWChantal Viola Weißfuß
Chantal Viola Weißfuß
SWSandra-Maria Wienhold
Sandra-Maria Wienhold
MBMagdalena Bürkle
Magdalena Bürkle
BGBaptiste GABORIEAU
Baptiste GABORIEAU
JBJudith Bushe
Judith Bushe
GNGeraldine Nouailles
Geraldine Nouailles
Phage therapy of ventilator-associated pneumonia (VAP) is of great interest due to the rising incidence of multidrug-resistant bacterial pathogens. However, natural or therapy-induced immunity against therapeutic phages remains a potential concern. In this study, we investigated the innate and adaptive immune responses to two different phage cocktails targeting either Pseudomonas aeruginosa or Escherichia coli—two VAP-associated pathogens—in naïve mice without the confounding effects of a bacterial infection. Active or UV-inactivated phage cocktails or buffers were injected intraperitoneally daily for 7 days in C57BL/6J wild-type mice. Blood cell analysis, flow cytometry analysis, assessment of phage distribution and histopathological analysis of spleens were performed at 6 h, 10 days and 21 days after treatment start. Phages reached the lungs and although the phage cocktails were slightly immunogenic, phage injections were well tolerated without obvious adverse effects. No signs of activation of innate or adaptive immune cells were observed; however, both active phage cocktails elicited a minimal humoral response with secretion of phage-specific antibodies. Our findings show that even repetitive injections lead only to a minimal innate and adaptive immune response in naïve mice and suggest that systemic phage treatment is thus potentially suitable for treating bacterial lung infections.